RRM2, which encodes ribonucleotide reductase, is overexpressed in aggressive basal-like and TNBC, where elevated levels correlate with adverse clinical features including larger tumor burden, lymph node involvement, and disease recurrence [103, 104]. The gene discussed is RRM2; the disease is neoplasm.